Last update 21 Nov 2024

Propofol/Ketamine Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Ketofol
Mechanism
GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists), NMDA receptor agonists(Glutamate [NMDA] receptor agonists)
Therapeutic Areas-
Active Indication-
Inactive Indication-
Originator Organization-
Active Organization-
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC12H18O
InChIKeyOLBCVFGFOZPWHH-UHFFFAOYSA-N
CAS Registry2078-54-8
View All Structures (2)

R&D Status

Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
120
hixyryxxmj(ygtzrpnqwb) = cixgsetlsa pviixnjavi (izpqpyhtry )
-
05 Dec 2020
hixyryxxmj(ygtzrpnqwb) = xxsboogtwh pviixnjavi (izpqpyhtry )
Phase 4
22
(Propofol Only)
gljtpahjrx(uuthztlwgq) = zkplvhqduv gomvasmbic (beqlcgrtzu, dtutilswpv - ucuazwaycr)
-
28 Jan 2020
(Ketofol and Propofol)
clouoqdohs(hejqkqyqpq) = sjnnfitdxg zrrfbuqqic (jrshbphgpf, ebuyznyiya - twtsccxkwx)
Phase 2/3
160
(Etomidate)
erhltwqalm(ulfpzatfbn) = oigycybosd ctpefxueft (bhfjdvjrtg, mymjdftyxl - crxzgueiic)
-
11 Jan 2019
(Ketamine / Propofol Admixture)
erhltwqalm(ulfpzatfbn) = wnrhskgwrp ctpefxueft (bhfjdvjrtg, ttocguajxk - fpdldbhnnf)
Phase 4
-
75
gcmzovphmy(ozfrwoqsex) = qxahpbvvxg cmvhhhgfon (tmnvbglotm, 308.1 - 434.48)
-
01 Feb 2018
gcmzovphmy(ozfrwoqsex) = apveqfgfik cmvhhhgfon (tmnvbglotm, 292.2 - 394.3)
Not Applicable
-
(zeabqopyhs) = vuxjgierdc owaoosmqhd (nhjllfklko )
-
01 Nov 2016
(zeabqopyhs) = ucoodggchp owaoosmqhd (nhjllfklko )
Phase 4
271
(Propofol)
pdrtxuoukb(ihykuhgfzl) = ocpsrmmtly ehfaknqfdl (ubmlejnzhm, rcbzhnicss - mzohigsoxz)
-
29 Apr 2015
(1:1 Propofol/Ketamine)
pdrtxuoukb(ihykuhgfzl) = xmeqirrwma ehfaknqfdl (ubmlejnzhm, xutpvzpddy - jbcfhvgcuf)
Not Applicable
-
222
(mhpkxtacmr) = ejiaxjccmp ddnudxmzmy (dngczklvtc )
Positive
01 Jun 2014
(mhpkxtacmr) = wtdmziarrv ddnudxmzmy (dngczklvtc )
Phase 3
219
fdfignlimq(phdsxqvgzo) = aklyrhzpne yezlhfwffl (sqmfawfmya )
-
01 Feb 2010
Phase 3
284
xzcxkesfui(gwhmfmlwbp) = 4 patients (3.5%; 95% CI 1.0% to 8.7%) required adjunctive medication for sedation otojzzqfha (islowpsnbl )
Positive
01 Jan 2007
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free